Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 2/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | CLK3 | P49761 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | WDR5 | P61964 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186207 | 1.00 | BDKRB1 (0.43) | BDKRB1OPRL1CNR1BTKPTK2 | |
| SCHEMBL186978 | 0.92 | BDKRB1 (0.43) | BDKRB1CNR1BTKPTK2RAF1 | |
| SCHEMBL2806693 | 0.92 | BDKRB1 (0.43) | BDKRB1CNR1BTKPTK2RAF1 | |
| SCHEMBL2804932 | 0.91 | BDKRB1 (0.48) | BDKRB1CNR1BTKPTK2RAF1 | |
| SCHEMBL2804934 | 0.91 | BDKRB1 (0.48) | BDKRB1CNR1BTKPTK2RAF1 | |
| SCHEMBL186165 | 0.90 | BDKRB1 (0.42) | BDKRB1OPRL1CNR1PTK2RAF1 | |
| SCHEMBL2809068 | 0.90 | BDKRB1 (0.42) | BDKRB1OPRL1CNR1PTK2RAF1 | |
| SCHEMBL185998 | 0.90 | BDKRB1 (0.41) | BDKRB1OPRL1PTK2RAF1CNR2 | |
| SCHEMBL2808383 | 0.90 | BDKRB1 (0.41) | BDKRB1OPRL1PTK2RAF1CNR2 | |
| SCHEMBL13128639 | 0.89 | BDKRB1 (0.40) | BDKRB1OPRL1PTK2CNR2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | BDKRB1 289/4885OPRL1 334/4885CNR1 211/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | BDKRB1 289/4885OPRL1 334/4885CNR1 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.